Cost-effectiveness in unstable economies: the case of sacubitril/valsartan in heart failure with reduced ejection fraction in Argentina

Figures

• 

  Fig. 1. One-way sensitivity analysis (Tornado) for social security health care payer. ICERs expressed as cost in Argentinian pesos (ARS) per QALY gained. Central line indicates the value of ICER in central estimation of every coefficient in the model; extremes of bars indicate value of ICER in the limits of 95% CI of the coefficients. Blue areas indicate the region of every bar towards lower values of the coefficient under concern; red areas indicate the region of every bar towards higher values of the coefficient being considered

• 

  Fig. 2. One-way sensitivity analysis (Tornado) for private health care payer. ICERs expressed as cost in Argentinian pesos (ARS) per QALY gained. Central line indicates the value of ICER in central estimation of every coefficient in the model; extremes of bars indicate value of ICER in the limits of 95% CI of the coefficients. Blue areas indicate the region of every bar towards lower values of the coefficient under concern; red areas indicate the region of every bar towards higher values of the coefficient being considered

• 

  Fig. 3. Probabilistic sensitivity analysis and 95% confidence interval ellipse for social security payer (after 1000 simulations) The red square is the deterministic ICER (cost per for QALY gained). The thick red line represents the probabilistic central estimation with an ICER = 390,667 ARS per QALY gained The dotted red line, below the thick red one, represents the probabilistic lower 95% confidence limit with an ICER = 274,242 ARS per QALY gained The dotted red line, above the thick red one, represents the probabilistic upper 95% confidence limit with an ICER = 708,550 ARS per QALY gained The dotted and hyphened grey lines represent 1 and 3 GDP per capita thresholds, respectively (1 GDP per capita = 520,405.79 ARS)

• 

  Fig. 4. Probabilistic sensitivity analysis and 95% confidence interval ellipse for private payer (after 1000 simulations) The red square is the deterministic ICER (cost per for QALY gained). The thick red line represents the probabilistic central estimation with an ICER = 378,882 ARS per QALY gained, The dotted red line, below the thick red one, represents the probabilistic lower 95% confidence limit with an ICER = 265,004 ARS per QALY gained. The dotted red line, above the thick red one, represents the probabilistic upper 95% confidence limit with an ICER = 697,756 ARS per QALY gained. The dotted and hyphened grey lines represent 1 and 3 GDP per capita thresholds, respectively (1 GDP per capita = 520,405.79 ARS)

• 

  Fig. 5. Probability for sacubitril/valsartan of being accepted as cost-effective for a social security payer. Value of ceiling ratio represents the range of cost-effectiveness thresholds. The curve represents the probability for sacubitril/valsartan of being Accepted as a cost-effective option, considering a range of cost-effectiveness thresholds. At (1 GDP per capita of 520,405.79 ARS the probability is 90%

• 

  Fig. 6. Probability for sacubitril/valsartan of being accepted as cost-effective for a private payer. Value of ceiling ratio represents the range of cost-effectiveness thresholds. The curve represents the probability for sacubitril/valsartan of being Accepted as a cost-effective option, considering a range of cost-effectiveness thresholds. At (1 GDP per capita of 520,405.79 ARS the probability is 92%